ECONOMIC ANALYSIS OF TORCH: ERLOTINIB VERSUS CISPLATIN AND GEMCITABINE AS FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Chung, Carmen [1 ]
Jiang, Haiyan [2 ]
Isaranuwatchai, Wanrudee
Di Maio, Mas-Simo [3 ]
Lau, Anthea [2 ]
Hoch, Jeffrey
Feld, Ronald [2 ]
Tsao, Ming-Sound [4 ]
Gridelli, Cesare [5 ]
Gallo, Ciro [6 ]
Ciardiello, Fortunato [6 ]
Butts, Charles A. [7 ]
Perrone, Francesco [3 ]
Leighl, Natasha B. [8 ]
机构：
[1] Univ Toronto, Toronto, ON M5S 1A1, Canada
[2] Univ Hlth Network, Toronto, ON, Canada
[3] Natl Canc Inst, Milan, Italy
[4] Princess Margaret Hosp, Toronto, ON, Canada
[5] Sg Moscati Hosp, Avellino, Italy
[6] Univ Naples 2, Naples, Italy
[7] Cross Canc Inst, Edmonton, AB, Canada
[8] Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
cisplatin and gemcitabine; erlotinib; advanced non-small cell lung cancer; economic analysis;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-020
引用
收藏
页码：S602 / S603
页数：2
相关论文
共 50 条
  • [1] Economic analysis of TORCH: Erlotinib versus cisplatin and gemcitabine as first-line therapy for advanced non-small cell lung cancer (NSCLC).
    Chung, Carmen
    Isaranuwatchai, Wanrudee
    Di Maio, Massimo
    Jiang, Haiyan
    Lau, Anthea
    Hoch, Jeffrey S.
    Feld, Ronald
    Tsao, Ming Sound
    Gridelli, Cesare
    Ciardiello, Fortunato
    Butts, Charles Andrew
    Gallo, Ciro
    Perrone, Francesco
    Leighl, Natasha B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [2] Phase II trial of gemcitabine and cisplatin as first-line treatment of advanced non-small cell lung cancer (NSCLC).
    Lee, NS
    Byun, JH
    Bae, SB
    Kim, CK
    Lee, KT
    Park, SK
    Park, KK
    Won, JH
    Hong, DS
    Park, HS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 701S - 701S
  • [3] A phase II trial of adding cetuximab to cisplatin and gemcitabine as first-line therapy in advanced non-small cell lung cancer (NSCLC)
    Barata, F.
    Parente, B.
    Teixeira, E.
    Costa, A.
    Fernandes, A.
    Pimentel, F. L.
    Carvalho, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] BIWEEKLY CISPLATIN AND GEMCITABINE AS FIRST-LINE TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER
    Benekli, Mustafa
    Gunaydin, Yusuf
    Inanc, Mevlude
    Ozkan, Metin
    Demirci, Ayse
    Demirci, Umut
    Suner, Ali
    Karaca, Halit
    Tonyali, Onder
    Berk, Veli
    Buyukberber, Suleyman
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S563 - S563
  • [5] Gemcitabine and cisplatin for advanced non-small cell lung cancer (NSCLC)
    Casal, J
    Grande, C
    Caeiro, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1083 - 1083
  • [6] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Faehling, M.
    Achenbach, J.
    Staib, P.
    Steffen, U.
    Tessen, H. W.
    Brugger, W.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    M. Faehling
    J. Achenbach
    P. Staib
    U. Steffen
    H. W. Tessen
    V. E. Gaillard
    W. Brugger
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 1375 - 1383
  • [8] Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Shi, C.
    Zhong, H.
    Zhang, W.
    Zhang, B.
    Zhong, R.
    Zhang, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S646 - S647
  • [9] Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)
    Faehling, M.
    Achenbach, J.
    Staib, P.
    Steffen, U.
    Tessen, H. W.
    Gaillard, V. E.
    Brugger, W.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (07) : 1375 - 1383
  • [10] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    ONKOLOGIE, 2003, 26 : 26 - 32
12345